| Literature DB >> 24160183 |
Geert Paes1, Dominique Paepe, Evelyne Meyer, Annemarie T Kristensen, Luc Duchateau, Miguel Campos, Sylvie Daminet.
Abstract
BACKGROUND: Diagnosing canine immune-mediated haemolytic anaemia (IMHA) is often challenging because all currently available tests have their limitations. Dogs with IMHA often have an increased erythrocyte osmotic fragility (OF), a characteristic that is sometimes used in the diagnosis of IMHA. Since the classic osmotic fragility test (COFT) is time-consuming and requires specialized equipment, an easy and less labour-intensive rapid osmotic fragility test (ROFT) has been used in some countries, but its diagnostic value has not yet been investigated.This study aimed to evaluate erythrocyte osmotic fragility in dogs with and without IMHA, to compare results of the classic (COFT) and rapid (ROFT) test and to assess the value of the ROFT as diagnostic test for canine IMHA.Nineteen dogs with IMHA (group 1a), 21 anaemic dogs without IMHA (group 1b), 8 dogs with microcytosis (group 2), 13 hyperlipemic dogs (group 3), 10 dogs with lymphoma (group 4), 8 dogs with an infection (group 5) and 13 healthy dogs (group 6) were included.In all dogs, blood smear examination, in-saline auto-agglutination test, Coombs' test, COFT and ROFT were performed. In the COFT, OF5, OF50 and OF90 were defined as the NaCl concentrations at which respectively 5, 50 and 90% of erythrocytes were haemolysed.Entities:
Mesh:
Year: 2013 PMID: 24160183 PMCID: PMC3816578 DOI: 10.1186/1751-0147-55-74
Source DB: PubMed Journal: Acta Vet Scand ISSN: 0044-605X Impact factor: 1.695
Signalment data for group 1a (IMHA), group 1b (anaemia, no IMHA), group 2 (microcytosis), group 3 (hyperlipidemia), group 4 (lymphoma), group 5 (infections) and group 6 (healthy)
| Shih Tzu (n = 3), Belgian Shepherd (n = 3), Kuvasz (n = 1), Maltese Dog (n = 1), Great Dane (n = 1), American Cocker Spaniel (n = 1), Miniature Pincher (n = 1), Rottweiler (n = 1), Border Collie (n = 1), American Staffordshire Terrier (n = 1), Fox Terrier (n = 1), Labrador Retriever (n = 1), Jack Russell Terrier (n = 1), Dutch Partridge Dog (n = 1), mixed breed (n = 1) | F (n = 6) | 4.9 ± 2.7 (0.5-10) | |
| FN (n = 5) | |||
| M (n = 6) | |||
| MN (n = 2) | |||
| Bernese Mountain Dog (n = 4), Jack Russell Terrier (n = 4), Belgian Shepherd (n = 2), mixed breed (n = 2), Maltese Dog (n = 2), Miniature Schnauzer (n = 2), Beagle (n = 1), Labrador Retriever (n = 1), Miniature Pincher (n = 1), Cavalier King Charles Spaniel (n = 1), Big Münsterländer (n = 1) | F (n = 6) | 7.2 ± 4.3 (0.5-14) | |
| FN (n = 5) | |||
| M (n = 8) | |||
| MN (n = 2) | |||
| Labrador Retriever (n = 2), Doberman Pincher (n = 1), Jack Russell Terrier (n = 1), Maltese Dog (n = 1), Yorkshire Terrier (n = 1), mixed breed (n = 1), American Staffordshire Terrier (n = 1) | F (n = 2) | 8.6 ± 3.5 (1–12) | |
| FN (n = 2) | |||
| M (n = 3) | |||
| MN (n = 1) | |||
| Mixed breed (n = 2), Yorkshire Terrier (n = 2), Jack Russell Terrier (n = 1), Boxer (n = 1), Fox Terrier (n = 1), Cavalier King Charles Spaniel (n = 1), Weimaraner (n = 1), English Cocker Spaniel (n = 1), Golden Retriever (n = 1), Newfoundlander (n = 1), Wolfspitz (n = 1) | F (n = 2) | 9.3 ± 2.9 (3–13) | |
| FN (n = 2) | |||
| M (n = 7) | |||
| MN (n = 2) | |||
| Vizla (n = 1), Bernese Mountain Dog (n = 1), American Cocker Spaniel (n = 1), Fox Hound (n = 1), Dogo Argentino (n = 1), Golden Retriever (n = 1), Border Collie (n = 1), American Staffordshire Terrier (n = 1), Daschound (n = 1), Bouvier des Flandres (n = 1) | F (n = 2) | 7.9 ± 2.4 (4–12) | |
| FN (n = 2) | |||
| M (n = 4) | |||
| MN (n = 2) | |||
| German Pointer (n = 1), Fila Brasileiro (n = 1), American Staffordshire Terrier (n = 1), Cavalier King Charles Spaniel (n = 1), Chow Chow (n = 1), Labrador Retriever (n = 1), Beauceron (n = 1), mixed breed (n = 1) | F (n = 4) | 6.7 ± 3.8 (2–13) | |
| M (n = 4) | |||
| Mixed breed (n = 3), Nova Scotia Duck Tolling Retriever (n = 2), Maltese Dog (n = 2), Labrador Retriever (n = 2), Jack Russell Terrier (n = 1), Boxer (n = 1), Border Collie (n = 1), English Staffordshire Terrier (n = 1) | F (n = 5) | 6.1 ± 3.5 (1–11) | |
| FN (n = 1) | |||
| M (n = 4) | |||
| MN (n = 3) |
The data for age are expressed as mean ± standard deviation (range).
F: female; FN: female neutered; M: male; MN: male neutered.
The clinical diagnosis for group 1a (IMHA), group 1b (anaemia, no IMHA), group 2 (microcytosis), group 3 (hyperlipidemia), group 4 (lymphoma), and group 5 (infections)
| Immune-mediated haemolytic anaemia | Primary immune-mediated haemolytic anaemia (n = 17), secondary immune-mediated haemolytic anaemia (n = 2): right hind limb abscess, after Permethrin and Imidacloprida treatment | |
| Anaemia, no immune-mediated haemolytic anaemia | Splenic hemangiosarcoma (n = 5), histiocytic sarcoma (n = 2), disseminated mastocytoma (n = 1), gastro-intestinal bleeding due to long-term NSAID administration (n = 2) and intestinal neoplasia (n = 2), coumarine intoxication (n = 2), methemoglobinemia due to onion intoxication (n = 1), blood loss due to immune-mediated thrombocytopenia (n = 2), chronic kidney disease (n = 1), hypoadrenocorticism (n = 1), factor X deficiency (n = 1), anaemia of inflammatory disease (n = 1) | |
| Microcytosis | Iron deficiency due to chronic gastro-intestinal blood loss (n = 6), hypoadrenocorticism (n = 1), portosystemic shunt (n = 1) | |
| Hyperlipidemia | Hyperadrenocorticism (n = 7), diabetic ketoacidosis with pancreatitis (n = 1), pancreatitis (n = 1), cholestatic liver disease (n = 1), hypothyroidism (n = 1), nephrotic syndrome (n = 1), primary hyperlipidemia (n = 1) | |
| Multicentric Lymphoma | B-cell lymphoma (n = 5), T-cell lymphoma (n = 2), lymphoma with unknown immunophenotype (n = 3) | |
| Infectious disease | Pyometra (n = 2), septic peritonitis (n = 2), prostatitis (n = 1), chronic Erlichiosis (n = 1), Leishmaniasis (n = 1), septic pericarditis (n = 1) |
aAdvantix®, Bayer Health Care, Brussels, Belgium.
Results of the packed cell volume, mean corpuscular volume, cholesterol and triglyceride concentration, number of spherocytes, in-saline auto-agglutination and Coombs’ test for group 1a (IMHA), group 1b (anaemia, no IMHA), group 2 (microcytosis), group 3 (hyperlipidemia), group 4 (lymphoma), group 5 (infections) and group 6 (healthy)
| 13.6 ± 4.8 | 17.9 ± 4.3 | 25.0 ± 14.7 | 46.8 ± 9.9 | 44.1 ± 11.8 | 30.3 ± 15.1 | 46.9 ± 3.6 | ||
| (7.6-23) | (7.0-25.5) | (11.0-55.2) | (18.2-57.7) | (20.5-59.4) | (14.9-61.4) | (41.7-53.2) | ||
| 76.7 ± 5.1 | 77.7 ± 9.3 | 57.1 ± 3.3 | 68.9 ± 8.1 | 70.4 ± 4.5 | 66.5 ± 5.4 | 68.7 ± 2.4 | ||
| (70.7-88.4) | (67.1-96.3) | (50.4-60.0) | (62.7-77.2) | (62.9-77.3) | (60.0-76.7) | (63.0-71.2) | ||
| 6.73 ± 1.37 | 4.68 ± 3.18 | 3.58 ± 1.83 | 16.6 ± 11.0 | 4.95 ± 1.44 | 6.33 ± 1.48 | 6.81 ± 1.45 | ||
| (5.3-8.53)* | (0.83-12.7)** | (2.48-8.35) | (6.26-48.38) | (2.77-7.11) | (4.0-9.0) | (4.42-9.15) | ||
| 0.87 ± 0.30 | 0.76 ± 0.28 | 0.71 ± 0.44 | 11.73 ± 9.36 | 0.75 ± 0.31 | 0.90 ± 0.34 | 0.89 ± 0.56 | ||
| (0.57-1.25)* | (0.41-1.19)** | (0.24-1.72) | (0.86-29.26) | (0.44-1.34) | (0.52-1.56) | (0.31-1.99) | ||
| <1 | 3 | 13 | 7 | 11 | 10 | 7 | 13 | |
| 1-3 | 2 | 4 | 1 | 2 | 0 | 0 | 0 | |
| 3-5 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | |
| ≥5 | 12 | 1 | 0 | 0 | 0 | 1 | 0 | |
| Positive | 16 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Negative | 3 | 21 | 8 | 13 | 10 | 8 | 13 | |
| Positive | 13 | 1 | 0 | 0 | 0 | 2 | 0 | |
| Negative | 4*** | 20 | 8 | 13 | 10 | 6 | 13 | |
The data of the packed cell volume, the mean corpuscular volume, the cholesterol and triglyceride concentration are expressed as mean ± standard deviation (range).
*Total serum cholesterol and triglyceride concentrations were measured in 4/19 group 1a dogs.
**Total serum cholesterol and triglyceride concentrations were measured in 13/21 group 1b dogs.
***Coombs’ test was performed in 17/19 group 1a dogs.
Results of the rapid osmotic fragility test (ROFT) and classic osmotic fragility test (COFT) for group 1a (IMHA), group 1b (anaemia, no IMHA), group 2 (microcytosis), group 3 (hyperlipidemia), group 4 (lymphoma), group 5 (infections) and group 6 (healthy)
| . | ||||||||
|---|---|---|---|---|---|---|---|---|
| 17 | 1 | 0 | 10 | 0 | 0 | 1 | ||
| 2 | 20 | 8 | 3 | 10 | 8 | 12 | ||
| 0.75 ± 0.11* | 0.51 ± 0.11 | 0.53 ± 0.13 | 0.64 ± 0.14* | 0.52 ± 0.06 | 0.49 ± 0.04 | 0.51 ± 0.04 | ||
| (0.51-0.85) | (0.37-0.83) | (0.43-0.81) | (0.43-0.84) | (0.44-0.66) | (0.44-0.52) | (0.46-0.54) | ||
| 0.64 ± 0.12* | 0.39 ± 0.06 | 0.39 ± 0.05 | 0.45 ± 0.05 | 0.42 ± 0.04 | 0.39 ± 0.04 | 0.44 ± 0.03 | ||
| (0.44-0.83) | (0.28-0.52) | (0.35-0.49) | (0.33-0.53) | (0.36-0.47) | (0.34-0.42) | (0.40-0.49) | ||
| 0.38 ± 0.17 | 0.27 ± 0.10 | 0.26 ± 0.09 | 0.34 ± 0.07 | 0.36 ± 0.04 | 0.27 ± 0.10 | 0.34 ± 0.09 | ||
| (0.28-0.64) | (0.06-0.43) | (0.10-0.36) | (0.18-0.40) | (0.31-0.45) | (0.07-0.35) | (0.06-0.40) |
Data of the COFT are expressed as mean ± standard deviation (range).
OF5, OF50, OF90 are the NaCl concentration at which respectively 5, 50 and 90% of RBCs are hemolysed.
OF5, OF50 or OF90 from all clinical groups (group 1–5) were compared with the control group (group 6). The global significance level was set at 0.05.
*Denotes a statistically significant difference from the control group for the respective response variable.
Figure 1Cumulative and derivative fragiligram for group 1a (IMHA), group 3 (hyperlipidemia) and group 6 (healthy dogs). The cumulative (dark line) and derivative (light line) fragiligrams are based on the mean values for OF5, OF50 and OF90 of group 1a (dogs with IMHA), group 3 (dogs with hyperlipidemia) and group 6 (healthy dogs) in the COFT. The figure shows a marked left shift of the cumulative and derivative fragiligram in dogs from group 1a, while no obvious left shift of the fragiligrams is present in dogs from group 3 or group 6. Furthermore, it can be noticed that the NaCl concentration at which 5% of the erythrocytes are haemolysed is higher for group 3 than for group 6, which indicates that in group 3 a small subpopulation of erythrocytes has an increased osmotic fragility.